Accessibility Menu
Aeon Biopharma logo

Aeon Biopharma(NYSEMKT) AEON

Market Cap$15.67MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-100%
5 Year-100%
1 Year-60%
1 Month+29%
$0.29
-7.07%
-0.02Today
After hours$0.29-$0.01 (-2.06%)
Aeon Biopharma last closing stock price
MetricPriceDate
Last closeUSD 0.312026-08-28
Aeon Biopharma stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+63.56%USD 0.192026-08-21
1 month+29.3%USD 0.242026-07-29
3 month-58.48%USD 0.762026-05-29
Year to date-71.44%USD 1.102025-12-31
1 year-59.6%USD 0.782025-08-28
3 year-99.89%USD 289.442023-08-29
5 year-99.96%USD 702.002021-08-25
Since inception-99.95%USD 694.802021-04-12

Aeon Biopharma Financials at a Glance

Market Cap

$15.67MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$54.62M

EPS (TTM)

-$3.77

P/E Ratio

-0.08

Dividend

$0.00

Beta (Volatility)

0.27 (Low)

Price

$0.29

Volume

506,764

Open

$0.31

Previous Close

$0.30

Daily Range

$0.29 - $0.31

52-Week Range

$0.18 - $1.45

Estimated Earnings Date

Nov 13, 2026

AEON News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Aeon Biopharma

AEON Biopharma develops treatments for chronic medical conditions using botulinum toxin. Its main product aims to help people with migraines and muscle disorders. The company focuses on improving quality of life for patients with difficult-to-treat conditions.

What’s in the AEON Toolbox?

  • ABP-450 (prabotulinumtoxinA): Botulinum toxin injection for migraines, muscle disorders, and stomach motility issues; all potential future revenue depends on this product.
  • Therapeutic Focus: Targets chronic migraine, cervical dystonia (neck muscle spasms), and gastroparesis (delayed stomach emptying).
  • Research and Development: No commercial products yet; all revenue depends on future approvals.

AEON’s Growth Spurt: The Highlights

  • Secured exclusive rights to ABP-450 from Daewoong Pharmaceutical in 2019.
  • Shifted strategy in July 2024 to pursue biosimilar approval pathway for ABP-450.
  • Launched analytical studies in late 2024 to support U.S. regulatory filings.
  • Started an equity offering program with Leerink Partners in August 2024.
  • Discontinued migraine clinical trials in May 2024 after not meeting study goals.

What Makes AEON Stand Out?

AEON holds exclusive rights to develop and sell ABP-450 for medical uses in major markets. Its focus on therapeutic—not cosmetic—applications sets it apart from other botulinum toxin companies. The company’s reimbursement model aims to avoid pricing pressures from cosmetic sales.

Five Things You Need to Know

  • No revenue reported for QQ2 2025, QQ2 2024, or QQ2 2023.
  • Net loss was $7 million in QQ2 2025, compared to $164 million net income in QQ2 2024 (driven by non-cash items).
  • Cash used in operations was $10 million for the six months ended June 30, 2025, improving 40% from prior year.
  • Cash and equivalents were $8.4 million as of June 30, 2025; runway expected into Q4 2025.
  • Company has five employees and relies on external funding for operations.

Bottom Line

AEON is a small biotech focused on developing a single therapeutic product. Its future depends on regulatory success and securing new funding.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

8

CEO

Robert E. Bancroft, MBA

Website

www.aeonbiopharma.com

Headquarters

Irvine, CA 92614, US

AEON Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

204.18%

Return on Capital

N/A

Return on Assets

-924.25%

Earnings Yield

-12.50%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$15.67MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

49.88M

Volume

506.76K

Avg. Volume

2.54M

Financials (TTM)

Gross Profit

-$39.00K

Operating Income

-$19.87M

EBITDA

-$25.68M

Operating Cash Flow

-$13.64M

Capital Expenditure

$0.00

Free Cash Flow

-$13.64M

Cash & ST Invst.

$3.43M

Total Debt

$2.78M

Aeon Biopharma Performance Analysis

Aeon Biopharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Aeon Biopharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Q22026-06-30N/A
Aeon Biopharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -27.25N/A
20232023-12-31USD -744.832633.1%
20242024-12-31USD 72.93N/A
20252025-12-31USD -3.95N/A
Aeon Biopharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3035.0%
Q42025-12-31-687.2%
Q12026-03-3190.6%
Q22026-06-3092.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$20.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$15.67MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.96M

N/A

Employees

8

N/A

Net Income

-$1.16M

+82.6%

EBITDA

-$5.91M

-37.4%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$3.43M

-59.3%

Total Debt

$2.78M

-83.1%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$2.51M

-84.5%

Short Term Debt

$263.00K

+8.7%

Return on Assets

-9.24%

N/A

Return on Invested Capital

13.88%

N/A

Free Cash Flow

-$3.70M

-76.9%

Operating Cash Flow

-$3.70M

-76.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CLRBCellectar Biosciences, Inc.
$2.51-0.79%
MRKRMarker Therapeutics, Inc.
$1.33-2.92%
BOLTBolt Biotherapeutics, Inc.
$3.98+4.19%
APMAptorum Group Limited
$8.26-14.84%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About AEON

What is the current price of Aeon Biopharma?

Aeon Biopharma is trading at $0.30 per share.

What is the 52-week range for Aeon Biopharma?

Over the past 52 weeks, Aeon Biopharma has traded between $0.18 and $1.45.

How much debt does Aeon Biopharma have?

As of the most recent reporting period, Aeon Biopharma reported total debt of $2.78M.

How much cash does Aeon Biopharma have on hand?

Aeon Biopharma reported $3.43M in cash and cash equivalents in its most recent financial results.

What is Aeon Biopharma’s dividend yield?

Aeon Biopharma does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services